Refractory Mycosis Fungoides and Sezary Syndrome
Also known as: Mycosis fungoides/Sezary syndrome refractory / Refractory Mycosis Fungoides/Sezary Syndrome / Cutaneous T-cell lymphoma refractory
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB12498 | Mogamulizumab | A monoclonal antibody used to treat relapsed or refractory mycosis fungoides or Sézary syndrome after attempting one other therapy. |
| Drug | Drug Name | Target | Type |
|---|---|---|---|
| DB12498 | Mogamulizumab | C-C chemokine receptor type 4 | target |
| Drug | Drug Name | Phase | Status | Count |
|---|---|---|---|---|
| DB16225 | Magrolimab | 1 / 2 | Active Not Recruiting | 1 |
| DB12498 | Mogamulizumab | 1 / 2 | Active Not Recruiting | 1 |
| DB00033 | Interferon gamma-1b | 2 | Completed | 1 |
| DB09037 | Pembrolizumab | 2 | Completed | 2 |